BBNX — Beta Bionics Balance Sheet
0.000.00%
- $474.89m
- $255.76m
- $100.25m
Annual balance sheet for Beta Bionics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 27.7 | 96.7 | 104 | 219 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0 | 4.45 | 12 | 19.9 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 28.5 | 104 | 133 | 268 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 6.87 | 6.2 | 11.4 | 15.2 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 35.5 | 110 | 150 | 329 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 8.87 | 10.6 | 21.1 | 30.9 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 22.5 | 51.4 | 73.6 | 41.1 |
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Total Equity | 13 | 58.6 | 76 | 288 |
| Total Liabilities & Shareholders' Equity | 35.5 | 110 | 150 | 329 |
| Total Common Shares Outstanding |